22nd week of 2017 patent applcation highlights part 6 |
Patent application number | Title | Published |
20170151175 | INFANT NUTRITION WITH LIPID GLOBULES TO INCREASE ENERGY EXPENDITURE AND METABOLIC FLEXIBILITY LATER IN LIFE - The present invention relates to nutrition for infants and young children with particular lipid globules, resulting in programming the metabolism to an increased energy expenditure and improved mitochondrial functioning later in life when exposed to a high fat, high energy diet. | 2017-06-01 |
20170151176 | GELATIN/PECTIN PARTICLES - Disclosed are particles comprising pectin and gelatin. The particles may be useful for preparing any of a variety products such as, for example, soft pharmaceutical capsules, hard pharmaceutical capsules, and foodstuffs. Also disclosed are methods for preparing the particles, the method comprising: (a) dissolving pectin in an aqueous solution to produce an aqueous solution of dissolved pectin; (b) mixing the aqueous solution of dissolved pectin with liquid gelatin to produce a gelatin/pectin mixture; (c) drying the gelatin/pectin mixture; and (d) milling the gelatin/pectin mixture to produce the plurality of particles. | 2017-06-01 |
20170151177 | LOXOPROFEN AND GAMMA-AMINOBUTIRIC ACID RECEPTOR AGONIST COMBINATIONS - This invention is a novel pharmaceutical composition comprising loxoprofen or a pharmaceutically acceptable salt thereof in combination with gamma-aminobutiric acid receptor agonist or a pharmaceutically acceptable salt thereof with anti-inflammatory, analgesic and myorelaxant activity. | 2017-06-01 |
20170151178 | EASILY DOSABLE SOLID PREPARATION - It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose. | 2017-06-01 |
20170151179 | Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof - A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate. | 2017-06-01 |
20170151180 | BUPRENORPHINE NANOPARTICLE COMPOSITION AND METHODS THEREOF - Stable nanoparticle compositions comprising buprenorphine and at least one biodegradable polymer. The disclosure also provides methods of controlling pain in an animal and methods of treating addiction in a human utilizing the stable nanoparticle compositions, as well as pharmaceutical formulations comprising the stable nanoparticle compositions. The stable nanoparticle compositions are capable of releasing buprenorphine over several days, weeks, or months following administration. The stable nanoparticle compositions of buprenorphine utilize biodegradable polymers capable of degrading into non-toxic components in the body of an animal and may be excreted in the urine of the animal following their metabolism in the body. The stable nanoparticle compositions can advantageously provide sustained release of buprenorphine in the body after a single administration without the need for surgical removal of implanted matrices subsequent to depletion of the drug. | 2017-06-01 |
20170151181 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES - The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles. | 2017-06-01 |
20170151182 | TREATMENT OF SCHIZOPHRENIA USING BETA-CARYOPHYLLENE AND CB2 RECEPTOR AGONISTS - Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists. | 2017-06-01 |
20170151183 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2017-06-01 |
20170151184 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2017-06-01 |
20170151185 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2017-06-01 |
20170151186 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2017-06-01 |
20170151187 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2017-06-01 |
20170151188 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 2017-06-01 |
20170151189 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 2017-06-01 |
20170151190 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2017-06-01 |
20170151191 | INTRANASAL ADMINISTRATION OF KETAMINE TO TREAT DEPRESSION - Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years). | 2017-06-01 |
20170151192 | METHODS, COMPOSITIONS AND DEVICES FOR TREATMENT OF MOTOR AND DEPRESSION SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - Disclosed is a method of treating Parkinson's disease and/or depression, and motor symptoms, non motor symptoms and depression symptoms associated with Parkinson's disease in a subject in need thereof, the method including administering to said subject a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration, and wherein a daily dose of the rasagiline or pharmaceutically acceptable salt thereof in the pharmaceutical composition is sufficient to inhibit monoamine oxidase (MAO)-A and MAO-B in a brain but insufficient to inhibit systemic MAO-A and therefore does not potentiate sympathetic cardiovascular activity associated with tyramine rich food consuming. Also, disclosed is a pharmaceutical composition including rasagiline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and a device configured for intranasal administration of a pharmaceutical composition including rasagiline or a pharmaceutically acceptable salt thereof to a subject. | 2017-06-01 |
20170151193 | PHARMACEUTICAL SOLUTION COMPRISING DOPAMINE FOR USE IN TREATING PARKINSON'S DISEASE - The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its firmation to its administration. | 2017-06-01 |
20170151194 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2017-06-01 |
20170151195 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators - The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y. | 2017-06-01 |
20170151196 | NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES - The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia. | 2017-06-01 |
20170151197 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF - The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia. | 2017-06-01 |
20170151198 | ORGAN PROTECTION SOLUTIONS AND METHOD OF USE - An organ protectant solution which is intravenously administered includes at least one oncotic agent and optionally a high concentration of cell-impermeant molecules. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, maintaining blood circulation and oxygenation of tissues, and extending the “Golden Hour” for traumatic and/or hemorrhagic shock patients. In addition, compositions comprising PEG-20k and methods of their use for preserving and/or reanimating harvested organs ex vivo for lengthy periods of time (e.g. at least about 8-24 hours) are also provided. | 2017-06-01 |
20170151199 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER - The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB. | 2017-06-01 |
20170151200 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IDIOPATHIC INFLAMMATORY MYOPATHIES - Administration of isoleucine, leucine and valine is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. This method is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. | 2017-06-01 |
20170151201 | COMPOSITIONS AND METHODS FOR TREATING FIBROMYALGIA - Embodiments of the invention generally relate to supplements for treating fibromyalgia and symptoms associated with fibromyalgia. | 2017-06-01 |
20170151202 | METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL OR MEMBRANE POLYUNSATURATED FATTY ACIDS - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2017-06-01 |
20170151203 | INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES - The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. | 2017-06-01 |
20170151204 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE - The present invention relates to the use of leukotriene B | 2017-06-01 |
20170151205 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects. | 2017-06-01 |
20170151206 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. | 2017-06-01 |
20170151207 | Ester and Cholinesterase Inhibitor in Long-Acting Nerve Block - Pharmaceutical compositions comprising an ester anesthetic and a cholinesterase inhibitor have been found to exhibit surprising and beneficial results in achieving a long-acting nerve block for example when administered to an interfascial plane or a peri-neural location in a subject. Such pharmaceutical compositions may also contain an amide anesthetic. Pharmaceutical compositions and methods of using such compositions as described herein provide a surprising and unexpected duration of pain control and a reduced need for the use of narcotics. | 2017-06-01 |
20170151208 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) - The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): | 2017-06-01 |
20170151209 | METHODS FOR TREATING BIPOLAR DISORDER - The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof. | 2017-06-01 |
20170151210 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX - The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure. | 2017-06-01 |
20170151211 | Desethylamiodarone for use in cancer treatment - The invention relates to a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, as well as pharmaceutical composition comprising the compound together with a pharmaceutically acceptable excipient, vehicle or carrier, for use in the treatment of cancer. | 2017-06-01 |
20170151212 | PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER - Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant. | 2017-06-01 |
20170151213 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2017-06-01 |
20170151214 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2017-06-01 |
20170151215 | USE OF ROTIGOTINE FOR TREATING THE RESTLESS LEG SYNDROME - This invention relates to the use of rotigotine for the effective treatment of Restless Leg Syndrome (RLS) as well as to a rotigotine-containing transepicutaneous pharmaceutical composition, provided in particular in the form of an acrylate- or silicone-based Transdermal Therapeutic System (US) having a surface area of 2.5 to 20 cm | 2017-06-01 |
20170151216 | TREATMENT OF AUTISTIC SPECTRUM DISORDER - A kit, optionally for treating a patient having ASD, is disclosed. The kit includes at least one first package and at least one second package. The first package contains an alpha-2 adrenergic agonist in an extended release dosage form. The second package contains inositol. | 2017-06-01 |
20170151217 | STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES - The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient. | 2017-06-01 |
20170151218 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER - The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: | 2017-06-01 |
20170151219 | ANTIPERSPIRANT AGENT - The present invention provides an antiperspirant which can effectively and safely control perspiration. The antiperspirant in accordance with an aspect of the present invention contains a mTOR inhibitor. The mTOR inhibitor can be rapamycin, a rapamycin derivative, or the like, and the antiperspirant can be used against hyperhidrosis and the like. | 2017-06-01 |
20170151220 | IBS MICROBIOTA AND USES THEREOF - The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin. | 2017-06-01 |
20170151221 | PHARMACEUTICAL COMPOSITIONS COMPRISING CEFEPIME OR SULBACTAM - Pharmaceutical compositions comprising a beta-lactam compound selected from cefepime, sulbactam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed. | 2017-06-01 |
20170151222 | SNORING TREATMENT - The present invention features compositions and methods for treatment of snoring. We describe compositions comprising an antihistamine or a pharmaceutically acceptable salt thereof and one or more dietary supplements or pharmaceutically acceptable salts thereof. The compositions can be administered to a subject suffering from snoring. | 2017-06-01 |
20170151223 | PHARMACEUTICAL COMPOSITION COMBINING AN ANTICONVULSANT AND A DERIVATE OF NICOTINIC ACID - The combination of gabapentin with lysine clonixinate (CLG) makes it possible to relieve neuropathic pain caused both by diabetic neuropathy and by an injury to the nerve. The CLG combination produces a synergy in the antiallodynic effect, when the allodynia has been generated by direct mechanical damage to nervous tissue or when it has been produced as a result of a diabetic pathology. The therapeutic effect of the CLG combination is 3 to 11 times greater than the effect of each of the drugs separately. | 2017-06-01 |
20170151224 | LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS - This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS. | 2017-06-01 |
20170151225 | QUINOLINE DERIVATIVES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND DISORDERS - Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca | 2017-06-01 |
20170151226 | Treatment of Breast Cancer with Liposomal Irinotecan - Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (MM-398). The breast cancer may be triple negative breast cancer (TNBC), estrogen receptor/progesterone receptor (ER/PR) positive breast cancer, ER-positive breast cancer, or PR-positive breast cancer, or metastatic breast cancer. | 2017-06-01 |
20170151227 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS - Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions. | 2017-06-01 |
20170151228 | Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Prodrugs of Oxymorphone and Uses Thereof - The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxymorphone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. | 2017-06-01 |
20170151229 | METHODS OF MANUFACTURING ORAL FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2017-06-01 |
20170151230 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE - Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided. | 2017-06-01 |
20170151231 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE - Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided. | 2017-06-01 |
20170151233 | METHOD OF TREATING NASOPHARYNGEAL CARCINOMA USING PERILLYL ALCOHOL DERIVATIVE - A method of treating nasopharyngeal carcinoma in a mammal includes delivering to the mammal a therapeutically effective amount of a perillyl alcohol (POH) carbamate which is a perillyl alcohol conjugated with temozolomide (TMZ). | 2017-06-01 |
20170151234 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases - The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-di-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD). | 2017-06-01 |
20170151235 | SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMID- AZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME - The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases. | 2017-06-01 |
20170151236 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Imidazo[1,2-a]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2017-06-01 |
20170151237 | PHARMACEUTICAL PREPARATION COMPRISING BREXPIPRAZOLE AND SUBSTITUTED BETA-CYCLODEXTRIN - Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted β-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted β-cyclodextrin. | 2017-06-01 |
20170151238 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 2017-06-01 |
20170151239 | 2,4-Pyrimidinediamine Compounds and Their Uses - The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. | 2017-06-01 |
20170151240 | F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy - Chemotherapy remains of limited use for the treatment of prostate cancer with only one drug, docetaxel, demonstrating a modest survival advantage for treatment of late-stage disease. Data from the NCI 60 cell line screen indicated that the castration-resistant prostate cancer cell lines PC3 and DU145 were more sensitive than average to the novel polymeric fluoropyrimidine (FP), F10, despite displaying less than average sensitivity to the widely-used FP, 5FU. In an embodiment of the present invention, F10 treatment of PC3 xenografts results in a significant survival advantage (treatment to control ratio (T/C) days=18; p<0.001; n=16) relative to control mice treated with saline. F10 (40 mg/kg/dose) was administered via jugular vein catheterization 3-times per week for five weeks. This aggressive dosing regimen was completed with no drug-induced weight loss and with no evidence of toxicity. F10 was also shown to sensitize PC3 cells to radiation and F10 was also shown to be a potent radiosensitizer of PC3 xenografts in vivo with F10 in combination with radiation resulting in significantly greater regression of PC3 xenografts than radiation alone. The results indicate that F10 in this pre-clinical setting is an effective chemotherapeutic agent and possesses significant radiosensitizing properties. | 2017-06-01 |
20170151241 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS - Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist. | 2017-06-01 |
20170151242 | COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS - A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration. | 2017-06-01 |
20170151243 | Methods for the Treatment of HER2 Amplified Cancer - Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib. | 2017-06-01 |
20170151244 | ORAL PHARMACEUTICAL COMPOSITION OF TOFACITINIB - The present invention relates to a dry process for the preparation of pharmaceutical compositions of tofacitinib comprising tofacitinib and one or more pharmaceutically acceptable excipients. Dry processes, such as direct compression or dry granulation, involve fewer and simpler process steps, thus preventing the loss of the active ingredient during processing. | 2017-06-01 |
20170151245 | METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES AND AMYLOID BETA AMYLOIDOSIS BY MODULATING CRF RECEPTOR SIGNALING - Methods for treating or preventing tauopathies and/or Aβ amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonist are provided. | 2017-06-01 |
20170151246 | METHODS OF EYE TREATMENT USING THERAPEUTIC COMPOSITIONS CONTAINING DIPYRIDAMOLE - A method comprising the step of: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of pterygium and pinguecula. | 2017-06-01 |
20170151247 | HSP90 INHIBITORS - The disclosure relates to Compounds of Formula (1): | 2017-06-01 |
20170151248 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS - Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I | 2017-06-01 |
20170151249 | COMBINATION THERAPY - The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor. | 2017-06-01 |
20170151250 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) - The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): | 2017-06-01 |
20170151251 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2017-06-01 |
20170151252 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,- 3-Thiazol-4-yl Amides - The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, | 2017-06-01 |
20170151253 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease - Novel methods and compounds for treating Alzheimer's Disease are provided. In one aspect, the invention provides methods for treating Alzheimer's Disease by administering certain phenothiazine derivatives. In one embodiment, the methods include administering an effective amount of a 3-oxo-7-dialkyl-amino-phenothiazine derivative, or 3-oxo-7-dialkyl-amino-phenothiazine. In another embodiment, the invention provides methods for treating Alzheimer's Disease by administering an effective amount of a 3,7-diazetidin-1-yl-phenothiazine or a derivative thereof. In another aspect, the invention provides novel azetidinyl phenothiazine compounds. | 2017-06-01 |
20170151254 | PHARMACEUTICAL PREPARATION FOR MASKED TASTE ORAL ADMINISTRATION, CONTAINING CLOMIPRAMINE - The present invention relates to a pharmaceutical preparation for oral administration comprising, as an active ingredient, clomipramine or a pharmaceutically acceptable salt thereof; and a cation exchange resin and an anion polymer as a taste masking agent, wherein the pharmaceutical preparation can be orally administered even while comprising a pharmaceutically effective amount of clomipramine because the unique tastes of clomipramine, particularly, all of the bitter taste, spicy taste and burning taste are effectively masked, and thus the convenience of drug intake and portability is improved, and a method for manufacturing thereof. | 2017-06-01 |
20170151255 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A method of treating non-small cell lung cancer and/or small cell lung cancer in a mammal comprises the step of administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1). | 2017-06-01 |
20170151256 | ANTITUMOR AGENT - To provide a pharmaceutical agent or an antitumor agent useful for the treatment and/or prevention of gastrointestinal cancer, leukemia, pituitary tumor, small cell lung cancer, thyroid cancer, and neuroastrocytoma. The antitumor agent containing, as an active ingredient, a 1,5-benzodiazepine derivative represented by the following formula (1): | 2017-06-01 |
20170151257 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2017-06-01 |
20170151258 | INTRANASAL BENZODIAZEPINE PHARMACEUTICAL COMPOSITIONS - The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition. | 2017-06-01 |
20170151259 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2017-06-01 |
20170151260 | CHEMICALLY STABLE COMPOSITIONS OF A PHARMACEUTICAL ACTIVE AGENT IN A MULTI-CHAMBERED DELIVERY SYSTEM FOR OROMUCOSAL DELIVERY - A kit for oromucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate oromucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH. | 2017-06-01 |
20170151261 | SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS - A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars. | 2017-06-01 |
20170151262 | SHIP INHIBITION TO INDUCE ACTIVATION OF NATURAL KILLER CELLS - The present invention relates to the use or SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation, a method of inhibiting SHIP to induce broad activation of natural killer (NK) cells to treat various diseases. | 2017-06-01 |
20170151263 | ANORDRIN COMPOSITIONS AND METHODS FOR TREATING DISEASES - The present invention provides methods and compositions for treating cancer, reducing side effects, and reducing postmenopausal symptoms comprising anordrin or analog thereof (such as anordrin) alone or in combination with at least one other agent selected from the group consisting of tamoxifen, raloxifene or functional equivalent thereof, and an aromatase inhibitor. | 2017-06-01 |
20170151264 | COMBINATION - The present invention provides a pharmaceutical composition which comprises (a) a compound which is an inhibitor of phosphoinositide 3-kinase delta or a pharmaceutically acceptable salt and/or solvate thereof, and (b) a corticosteroid. | 2017-06-01 |
20170151265 | PULMONARY INTERSTITIAL PNEUMONIA TREATMENT - Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic and-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as non-steroidal anti-inflammatory drugs, anti-inflammatory diets, and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing the discontinuation or reduction of toxic anti-inflammatory therapy while maintaining low inflammation using non-toxic therapy. | 2017-06-01 |
20170151266 | METHODS AND COMPOSITIONS FOR ENHANCED DRUG DELIVERY TO THE EYE AND EXTENDED DELIVERY FORMULATIONS - The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents. | 2017-06-01 |
20170151267 | COMPOSITIONS AND PRODUCTS FOR USE IN THE TREATMENT OF BONE FRACTURES AND DEFECTS - The invention relates to methods for treatment of bone fractures and defects, in particular to method that accelerate fracture healing, and to compositions, injectable in situ depot forming formulations and patches comprising at least one biodegradable polymer, an androgen receptor agonist and a bisphosphonate or pharmaceutically acceptable salt thereof for use in such methods. | 2017-06-01 |
20170151268 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF - Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said glycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses. | 2017-06-01 |
20170151269 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF - Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said glycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses. | 2017-06-01 |
20170151270 | GM-CSF-PRODUCING T-CELL CONTROL AGENT AND Th1/Th2 IMMUNE BALANCE REGULATOR - The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient: | 2017-06-01 |
20170151271 | Novel Androgen Effectors - The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding. | 2017-06-01 |
20170151272 | A NOVEL PHARMACEUTICAL COMPOSITION OF SOFOSBUVIR AND RIBAVIRIN - This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin as active agents with at least one pharmaceutically acceptable excipient, wherein at least one of the active agents is in the form of controlled release, for use in the treatment of hepatitis C virus infections, chronic hepatitis C, hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation. | 2017-06-01 |
20170151273 | OPHTHALMIC FORMULATIONS - The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof. | 2017-06-01 |
20170151274 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNITY - The present disclosure relates generally to immunostimulatory compositions, and more specifically to immunostimulatory compositions containing a β-glucan preparation, a | 2017-06-01 |
20170151275 | THE USE OF DEXTRAN SULFATE HAVING AN AVERAGE MOLECULAR WEIGHT BELOW 10000 DA FOR INDUCING ANGIOGENESIS IN A SUBJECT - The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia. | 2017-06-01 |